Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 (Ruzasvir) With or Without Ribavirin in Non-cirrhotic or Cirrhotic.

Slides:

Advertisements

Similar presentations

Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.

Advertisements

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-1 Phase 3 Treatment Naïve Source: Afdhal N, et al. N.

Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Weight-based Ribavirin in HCV GT 2,3 Phase 4 Treatment Naïve, Chronic HCV Zeuzem S, et.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Phase 3 Treatment Experienced Source: Afdhal N, et.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir for 8 or 12 weeks in HCV GT1 ION-3 Phase 3 Treatment Naïve Kowdley K, et al. N Engl J Med.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV GT 4 Egyptian Ancestry Trial Phase 2 Ruane PJ, et al. J Hepatol. 2015;62:

Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:

Roth D. EASL 2015, Abs. LP02 C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR + EBR (Intensive.

OBV/PTV/r Open label years Chronic HCV infection Genotype 1b Treatment-naïve or failure to PEG-IFN + RBV HCV RNA > 10,000 IU/ml Without or with cirrhosis*

Hepatitis web study Hepatitis web study Sofosbuvir + RBV in Treatment-Naïve Genotypes 2,3 FISSION Trial* Phase 3 *Note: Published in NEJM in tandem with.

> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.

Forns X. J Hepatology 2015; 63: C-SALVAGE Study: grazoprevir + elbasvir + RBV in genotype 1 with failure to PI-based regimen –NS3 and NS5A RAVs.

Roth D. Lancet 2015; Oct 6; 386: C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR.

LDV/SOF Failure Open-label W24 Chronic HCV infection Genotype 1 Failure to achieve SVR on LDV/SOF-containing regimen Compensated cirrhosis (liver biopsy.

LDV/SOF Open-label Chronic HCV infection Genotype 1 Failure to achieve SVR 12 on a short-course of 1 st line LDV/SOF-containing regimen No cirrhosis N.

Hepatitis web study Hepatitis web study Elbasvir-Grazoprevir in Treatment-Naïve HCV Genotype 1, 4 or 6 C-EDGE Treatment Naïve (TN) Phase 3 Treatment Naïve.

Phase 3 Treatment Experienced

Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Naïve GT 1-6 POLARIS-2

Phase 3 Treatment Experienced

Sofosbuvir-Velpatasvir-Voxilaprevir in GT 3 and Cirrhosis POLARIS-3

Design Randomisation * 1 : 1 Open-label W16 W24 > 18 years

Interim Analysis of a 3-Year Follow-up Study of NS5A and NS3 Resistance-Associated Variants After Treatment With Grazoprevir-Containing Regimens in Patients.

No HBV or HIV co-infection

Phase 3 Treatment-Naïve and Treatment-Experienced

Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial

C-ISLE study: EBR/GZR + SOF + RBV in genotype 3 and cirrhosis

ARV-trial.com C-CREST study, Part B: uprifosbuvir (MK-3682)/GZR/ruzasvir (MK-8408) fixed-dose combination + RBV for genotypes 1, 2 and 3 - Phase II Randomisation.

Phase 3 Treatment-Naïve and Treatment-Experienced

Phase 3b Treatment-Naive

Design Randomisation* 1 : 1 Open-label W12

Phase 3 Treatment Experienced

Phase 3 Treatment-Naïve and Treatment-Experienced

Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in GT1b TURQUOISE-III

C-BREEZE-2 Study: ruzasvir + uprifosbuvir for 12 weeks in genotype 1-6

Phase 2 Treatment Naïve HIV Coinfection

DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?

Phase 2 Treatment Naïve (unfavorable baseline treatment characteristics) Ledipasvir-Sofosbuvir +/- 3rd DAA in HCV Genotype 1 NIAID SYNERGY: Genotype.

Case 53-year-old Black Man

Phase 2 Treatment Naïve Injection Drug Use

HCV Care in Unique Patient Populations

Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1 C-SALVAGE

Phase 3 Treatment-Naïve and Treatment-Experienced

Simeprevir in HIV Coinfection, GT-1 C212 Trial

Phase 3 Treatment Naïve HIV Coinfection

Phase 2 Treatment Naïve Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Naïve HCV GT 2, 4, 5, or 6 C-SCAPE Brown A, et al. EASL 2015; Abstract P0771.

Phase 3 Treatment-Naïve and Treatment-Experienced

Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I

New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges

New Agents, New Regimens, New Strategies

Phase 3 Treatment-Naïve and Treatment-Experienced

Volume 59, Issue 4, Pages (October 2013)

Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2

Phase 2 Treatment Naïve and Treatment Experienced

Ledipasvir-Sofosbuvir +/- Ribavirin for 8 or 12 weeks in HCV GT1 ION-3

Phase 2b Treatment Naïve and Treatment Experienced

Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naïve patients with Chronic HCV GT 1, GT 4 and GT 6 Infection (C-CORAL): A Phase III Randomized.

Elbasvir/Grazoprevir plus Sofosbuvir ± Ribavirin in Treatment-naive and Treatment-experienced Patients with Hepatitis C Virus Genotype 3 Infection and.

Phase 3 Treatment Naïve and Treatment Experienced HIV Coinfection

Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV.

ARV-trial.com C-CREST study, Part B: uprifosbuvir (MK-3682)/GZR/ruzasvir (MK-8408) fixed-dose combination + RBV for genotypes 1, 2 and 3 - Phase II Randomisation.

Phase 2 Treatment Naïve Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve HCV Genotype 1 or 3 C-SWIFT Poordad F, et al. EASL 2015; Abstract O006.

REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR:

Phase 3 Treatment-Naïve and Treatment-Experienced

Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682 / Grazoprevir / MK-8408 (Ruzasvir) in Cirrhotic or Non-cirrhotic Patients with Chronic.

Phase 3 Treatment-Naïve and Treatment-Experienced

SOF/VEL ± RBV in genotype 3 with compensated cirrhosis

Telaprevir in Treatment Experienced GT-1 PROVE3

Phase 3 Treatment-Naïve and Treatment-Experienced

Phase 3 Treatment-Naïve and Treatment-Experienced

Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2

Presentation transcript:

Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 (Ruzasvir) With or Without Ribavirin in Non-cirrhotic or Cirrhotic Patients with Chronic HCV GT1, 2 or 3 Infection (Part B of C-CREST-1 & -2)

Disclosures for Eric Lawitz

Acknowledgements

MK3: MK-3682/Grazoprevir/Ruzasvir

Key Inclusion & Exclusion Criteria

Endpoints and Populations

SVR12 (Full Analysis Set): 8, 12 or 16 Weeks

SVR12 (Full Analysis Set): 8, 12 or 16 Weeks

SVR12 (Full Analysis Set): 8, 12 or 16 Weeks

SVR12 (Per Protocol): 8, 12 or 16 Weeks

SVR12 (Per Protocol) GT1 Patients With or Without Cirrhosis

SVR12 (Per Protocol) GT2 or GT3 Patients With or Without Ribavirin

SVR12 (Per Protocol) GT2 or GT3 Patients With or Without Cirrhosis

SVR12 (Per Protocol) GT3 Patients by Prior Treatment Experience

SVR12 (Per Protocol) GT3 Treatment-experienced Patients with Cirrhosis

Selected NS5A RAVs (28, 30, 31, 93): Prevalence and Impact on Efficacy in GT1

Selected NS5A RAVs: Prevalence and Impact on Efficacy of L31M in GT2 and Y93H in GT3

Conclusions